VKTX241101P65000
- 0.10
- -0.06-37.50%
Viking Therapeutics Newsroom
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $125
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $138
Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Viking Therapeutics (VKTX) and Boston Scientific (BSX)
Viking Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $125
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF) and Viking Therapeutics (VKTX)
Buy Rating Affirmed for Viking Therapeutics on Promising VK0214 and VK2735 Clinical Data
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95